Study detail
RecruitingPhase 1
ACR-2316-101: Phase 1 Study of ACR-2316 in Subjects With Advanced Solid Tumors
Acrivon Therapeutics
Summary
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Description
The Phase 1 monotherapy clinical trial for ACR-2316 is designed to assess the safety and tolerability of ACR-2316. Additional objectives include the determination of the maximal tolerated dose and recommended Phase 2 monotherapy dose, characterization of the pharmacokinetic profile and pharmacogenomics, and preliminary evaluation of anti-tumor activity.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers